There are many inherited retinal diseases which could be addressed by Gene Editing. The most relevant example is IMO $EDIT-101 🧵👇 - a CRISPR/Cas9 Gene Editing therapy designed to treat Leber Congenital Amaurosis type 10 (LCA10), a rare genetic form of blindness caused by mutations in the CEP290 gene. It showed very promising results until @editasmed decided to discontinue it.

Curious what diseases are amenable to an Ntla type gene disruptor therapy.

From its updated corporate presentation it seems that $NTLA has recently terminated its ongoing collaboration with @SparingVision - a French biotech company focused on developing treatments for ocular Genetic Diseases.🧵👇 According to the collaboration agreement that was signed in 2021 $NTLA has acquired 10% of @SparingVision equity and was supposed to provide funding of up to $200M for the development of 3 ocular drugs with $NTLA owning the rights for 2 out of the 3 and all commercial rights in the US and 50% of non-us rights. IMO that is a huge corporate mistake and a very bad call to give up such a lucrative market.

At The 1st Japan IRD Innovation Summit in Tokyo, our CEO Stéphane Boissel represented SparingVision at this inaugural event dedicated to innovation in inherited retinal diseases. Great to connect with key stakeholders across research, to advance the development of gene therapies.

SparingVision has completed dosing SPVN06, a novel gene-agnostic adeno-associated virus (AAV) gene therapy designed to slow cone photoreceptor degeneration in retinitis pigmentosa (RP), in the multicenter Phase I/II PRODYGY trial hubs.li/Q042SC3-0

🌍Today is the International Day of Women and Girls in Science! 🤝 At SparingVision, we are proud to work alongside women whose passion and curiosity advance our research every day. #STEM #GenomicMedicines #Ophthalmology #GeneTherapy

Meet Pauline Jacquety, our Regulatory Affairs Senior Manager, who shares her experience as part of a team dedicated to developing and implementing regulatory strategies across the SparingVision pipeline. 🌟 Learn more here: sparingvision.com/blog/ #GenomicMedicines

Season’s Greetings from all of us at SparingVision! ✨ Wishing you joyful and meaningful holidays. We’re excited to continue our mission in 2026 and share what’s ahead! 🌟 #HappyHolidays #GenomicMedicines #Ophthalmology #GeneTherapy

🌟 Wishing those who celebrate a happy Thanksgiving from all of us at SparingVision 💙

SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis pigmentosa (RP). hubs.li/Q03SfSKW0

SparingVision doses first patient in NYRVANA clinical trial of SPVN20 for retinitis pigmentosa: hubs.li/Q03S4rkt0

SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis pigmentosa (RP). hubs.li/Q03RRZ0p0

SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis pigmentosa (RP). hubs.li/Q03Q-3w70

I hope that the patient recovers and that safety issues will be put to rest as $NTLA needs this to be resolved ASAP.

1/🚨SparingVision has announced that the first patient has been dosed in its NYRVANA clinical trial aimed to evaluate SPVN20 - a gene-agnostic, intravitreal AAV-based Gene Therapy designed to restore visual acuity and color vision in Retinitis pigmentosa (RP) patients. $NTLA $XBI

Big news from @SparingVision, an #RDFund portfolio company: the first patient has been dosed in the NYRVANA trial of #SPVN20 for advanced #RP — now expanding from Belgium to France and Ireland. retinaldegenerationfund.org/…

💡Stephane Boissel, President & CEO of SparingVision will be participating in an insightful conference call on the Development of the Next Generation of Innovations in Ophthalmology hosted by ICR Healthcare. 📅: October 30 12:00–1:00PM ET

We were honored to sit alongside industry leaders from @4DMolecular, @ComplementTx and @SparingVision during yesterday's panel at @ChardanCM’s 9th Annual Genetic Medicines Conf. and share how #Ocugen is driving innovation for blindness diseases. #Biotech #Investment

🏃‍♀️Two of our colleagues recently took on a race from Paris to Versailles! At SparingVision, we share the same values that drive athletes: determination, teamwork & the will to go further. Bravo Lucile & Benoit 👏 #TeamSpirit #Innovation #Biotech #Running #ParisRace #SparingVision